4basebio Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Heikki Lanckriet

Chief executive officer

UK£441.2k

Total compensation

CEO salary percentage71.3%
CEO tenureno data
CEO ownership8.6%
Management average tenureno data
Board average tenureno data

Recent management updates

Recent updates

CEO Compensation Analysis

How has Heikki Lanckriet's remuneration changed compared to 4basebio's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-UK£10m

Mar 31 2024n/an/a

-UK£9m

Dec 31 2023UK£441kUK£315k

-UK£8m

Sep 30 2023n/an/a

-UK£7m

Jun 30 2023n/an/a

-UK£6m

Mar 31 2023n/an/a

-UK£6m

Dec 31 2022UK£449kUK£300k

-UK£5m

Sep 30 2022n/an/a

-UK£5m

Jun 30 2022n/an/a

-UK£4m

Mar 31 2022n/an/a

-UK£4m

Dec 31 2021UK£428kUK£267k

-UK£3m

Sep 30 2021n/an/a

-UK£3m

Jun 30 2021n/an/a

-UK£2m

Mar 31 2021n/an/a

-UK£1m

Dec 31 2020UK£22kUK£22k

-UK£719k

Compensation vs Market: Heikki's total compensation ($USD554.47K) is about average for companies of similar size in the German market ($USD782.05K).

Compensation vs Earnings: Heikki's compensation has been consistent with company performance over the past year.


CEO

Heikki Lanckriet (47 yo)

no data

Tenure

UK£441,200

Compensation

Dr. Heikki Lanckriet, Ph.D. serves as Director at Biofrontera Inc. since July 07, 2023. He served as Member of Supervisory Board at Epigenomics AG since June 2022 until 2024. He serves as Non-executive Dir...